SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic assays, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces results from a prospective study
showing Target Selector™ was highly accurate in monitoring HER2
alterations in patients with metastatic breast cancer. The
results were featured yesterday in a poster presentation by
Vered Stearns, M.D., professor of
oncology, breast cancer research chair in oncology, and director of
the Women's Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns
Hopkins Sidney Kimmel Cancer Center, at the virtual 2020 San
Antonio Breast Cancer Symposium® (SABC®). The poster can be
found under the "breast cancer" tab here.
"Approximately 20% of newly diagnosed breast cancer is HER2
positive, but during treatment and as the disease progresses, HER2
receptor conversion may occur," said Dr. Stearns. "Once
breast cancer metastasizes, it may be difficult to access multiple
sites or perform serial tissue biopsies to monitor for
conversion. In this study, liquid biopsy testing proved to be
a highly sensitive and specific mechanism for monitoring HER2
receptor changes over time."
"Target Selector™ has been shown to be a highly sensitive
blood-based testing method for identifying changes in HER2 status,
and is less invasive, more time efficient and more cost effective
compared to tissue biopsy," said Michael
Nall, President and CEO. "Target Selector™ provides
critical information to identify patients who may benefit from the
addition of anti-HER2 therapy and those on anti-HER2 therapy for
whom additional therapeutic options may warrant consideration."
About SABCS®
Since 1977 the San Antonio Breast Cancer
Symposium® (SABCS®) has been the leading scientific conference for
basic scientists, physician-scientists, clinical investigators and
breast care providers, and advocates seeking an exchange of new
information in experimental biology, etiology, prevention,
diagnosis and therapy of premalignant breast disease and breast
cancer. Founded, owned and operated by UT Health San Antonio,
the symposium has grown to a five-day event attended by an
international audience of academic investigators and private
physicians from over 80 countries to attain information through
abstract presentations, panel discussions, research findings and
state-of-the-art educational sessions. UT Health San Antonio,
the American Association for Cancer Research (AACR) and Dan L
Duncan Comprehensive Cancer Center at Baylor
College of Medicine support SABCS, which provides education
and accessibility to the latest information regarding the
prevention, diagnosis and treatment of premalignant breast cancer
and breast disease. For more information about the symposium,
please visit www.sabcs.org.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company
uses its proprietary liquid biopsy technology to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands
of tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options.
Additionally, Biocept is offering nationwide COVID-19 polymerase
chain reaction (PCR) testing to support public health efforts
during this unprecedented pandemic. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding Target Selector being less invasive, more time
efficient and more cost effective compared to tissue biopsy, Target
Selector providing critical information to identify patients who
may benefit from the addition of anti-HER2 therapy and those on
anti-HER2 therapy for whom additional therapeutic options may
warrant consideration, the ability of our tests to provide
clinically actionable information and the ability of Biocept's
platform to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risks and uncertainties, including the risk that our
products and services may not perform as expected. These and other
risks are described in greater detail under the "Risk Factors"
heading of our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-liquid-biopsy-demonstrated-high-accuracy-when-used-for-monitoring-the-progression-of-metastatic-breast-cancer-in-study-conducted-at-johns-hopkins-sidney-kimmel-cancer-center-301190300.html
SOURCE Biocept, Inc.